IL17A and myeloid sarcoma: Specifically, the increased expression of IL-17 and IL-22 receptors were observed by Kebir H et al. in the blood-brain barrier endothelial cells (BBB-ECs) from multiple sclerosis (MS) lesions, whereas IL-17 receptor inhibitor significantly alleviated the inflammation damage of central nervous system, which suggested that the brain damage of MS patients was related to the involvement of IL-17 [16].